Neuland Laboratories
- Market cap
- ₹ 24,132 Cr.
- P/E
- 51.6x
- P/B
- 12.96x
- 52-week range
- 11,500 – 24,225
- ROE
- 21%
- ROCE
- 26%
- Dividend yield
- 0.2%
- Debt / equity
- 0.16
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Neuland Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)51.6 against a typical 34.3: pricier than most peers (1st = cheapest).160th of 220
- Sales growth+119.1% against a typical +15.6% from a year earlier.14th of 197
- Profit growth+957.1% against a typical +18.9% from a year earlier.5th of 160
- Share price, 3 months+1.8% against a typical −0.5%.90th of 200
- Size₹ 24,132.3 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).23rd of 199
Latest announcements
Exchange filings and their impact on the company.
- US FDA closed Unit 3 inspection with clean EIR, clearing regulatory overhang.
Neuland Laboratories said the US FDA has issued an Establishment Inspection Report for its Unit 3 plant at Gaddapotharam after an inspection from August 10-14, 2026. The agency has concluded the inspection as closed. This clears the regulatory overhang on the key US-supply facility and supports business continuity and future approvals.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A+ by 2 agencies- All agencies agree and none has raised a warning.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil A+ | Positive | 25 Aug 2026 |
| India Ratings | IND A+; IND A1 | Positive | 13 Jul 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 25 Aug 2026 | Rating action | Crisil A+ | — | CRISIL | ₹ 1,528 Cr. | |
| 13 Jul 2026 | Reaffirmed | IND A+ | — | India Ratings | ₹ 1,528.02 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 3 Nov 2026Upcoming | Financial Results | Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2026 |
| 5 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 12 May 2026 | Financial Results/Dividend | Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026, And; To Recommend Final Dividend, If Any, For The Financial Year Ended March 31, 2026 |
| 9 Feb 2026 | Financial Results | Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2025 |
| 7 Nov 2025 | Financial Results | To consider and approve the financial results for the quarter and half year ended September 30, 2025 |
| 31 Jul 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 15 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 418 | 393 | 385 | 440 | 311 | 398 | 328 | 293 | 514 | 440 | 776 | 642 |
| Expenses | 280 | 272 | 278 | 316 | 249 | 311 | 277 | 258 | 359 | 363 | 469 | 419 |
| Operating Profit | 137 | 121 | 107 | 123 | 62 | 87 | 51 | 34 | 156 | 77 | 307 | 223 |
| OPM % | 33% | 31% | 28% | 28% | 20% | 22% | 16% | 12% | 30% | 18% | 40% | 35% |
| Other Income | 3 | 2 | 5 | 25 | 4 | 60 | 7 | 8 | 2 | 8 | 12 | 8 |
| Interest | 4 | 4 | 4 | 3 | 1 | 2 | 2 | 5 | 5 | 7 | 7 | 7 |
| Depreciation | 15 | 15 | 16 | 16 | 16 | 16 | 17 | 20 | 23 | 24 | 25 | 27 |
| Profit before tax | 122 | 104 | 92 | 130 | 49 | 128 | 39 | 18 | 129 | 54 | 287 | 198 |
| Tax % | 27% | 22% | 27% | 25% | 34% | 20% | 29% | 21% | 25% | 26% | 26% | 25% |
| Net Profit | 89 | 81 | 68 | 98 | 33 | 102 | 28 | 14 | 97 | 41 | 213 | 148 |
| EPS in Rs | 69.56 | 63.44 | 52.66 | 76.28 | 25.6 | 79.18 | 21.68 | 10.83 | 75.49 | 31.62 | 165.76 | 115.1 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 15%
- 5 Years
- 17%
- 3 Years
- 19%
- TTM
- 78%
- 10 Years
- 29%
- 5 Years
- 39%
- 3 Years
- 30%
- TTM
- 278%
- 10 Years
- 37%
- 5 Years
- 71%
- 3 Years
- 83%
- TTM
- —
- 10 Years
- 14%
- 5 Years
- 18%
- 3 Years
- 20%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Neuland Laboratories | ₹ 20,045.00 | ₹ 24,132 Cr. | 51.6x | 13x | 21% | — |
| Aurobindo Pharma | ₹ 1,569.30 | ₹ 90,294 Cr. | 25.1x | 2.4x | 9.9% | 10.4% |
| Pfizer | ₹ 3,610.35 | ₹ 16,513 Cr. | 27.5x | 5x | 17.2% | 28.7% |
| Unichem Laboratories | ₹ 470.00 | ₹ 3,309 Cr. | 54.3x | 1.5x | 9.8% | 11.5% |
| Jagsonpal Pharmaceuticals | ₹ 213.00 | ₹ 1,402 Cr. | 34.3x | 5.4x | 16.7% | 15% |
| Themis Medicare | ₹ 90.00 | ₹ 826 Cr. | 632.2x | 2.5x | 0.3% | 0.3% |
Management
- Davuluri Rama Mohan Rao
- Executive Chairman of the Board
- Davuluri Saharsh Rao
- Chief Executive Officer, Managing Director
- Davuluri Sucheth Rao
- Executive Vice Chairman of the Board
- Abhijit Majumdar
- Chief Financial Officer
- Sharadsrikar V. Kotturi
- Chief Scientific Officer
- Sarada Bhamidipati
- Compliance Officer, Company Secretary
- Ashutosh Kumar Sinha
- Chief Quality Officer
Prices are delayed and for information only. Nothing on this page is investment advice.